Energy Specific Far Infrared Radiation Treatment for Hyperparathyroidism

NCT ID: NCT00573573

Last Updated: 2009-03-24

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE1

Total Enrollment

2 participants

Study Classification

INTERVENTIONAL

Study Start Date

2007-01-31

Study Completion Date

2009-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

A study to determine the possibility of using far infrared radiation to treat Hyperparathyroidism.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Overactive parathyroid glands secrete an excess of parathyroid hormones, resulting in increased levels of calcium in the blood stream, which can lead to weakening of the bones and to kidney stones.

We are postulating that the non-invasive energy specific electromagnetic radiation of the central nervous system, the viscera and the endocrine system has the potential to stop the over secretion of the parathyroid hormones and normalize the body's metabolic functions.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hyperparathyroidism

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1

Group Type OTHER

Far Infrared Radiation

Intervention Type RADIATION

Far Infrared Radiation (5μm to 20μm wavelength) for 30 to 40 minutes each session.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Far Infrared Radiation

Far Infrared Radiation (5μm to 20μm wavelength) for 30 to 40 minutes each session.

Intervention Type RADIATION

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Persons with parathyroid disease

Exclusion Criteria

* None
Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

GAAD Medical Research Institute Inc.

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

GAAD Medical Research Institute Inc.

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Ken Nedd, M.D.

Role: STUDY_DIRECTOR

GAAD Medical Research Institute Inc.

Kwasi Donyina, Ph.D.

Role: STUDY_CHAIR

GAAD Medical Research Institute Inc.

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

The Centre for Incurable Diseases

Toronto, Ontario, Canada

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Canada

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

GAAD-HT-CTP1

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Neuro RX Gamma - Pivotal Phase
NCT03484143 SUSPENDED NA